JP2011526616A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526616A5
JP2011526616A5 JP2011515631A JP2011515631A JP2011526616A5 JP 2011526616 A5 JP2011526616 A5 JP 2011526616A5 JP 2011515631 A JP2011515631 A JP 2011515631A JP 2011515631 A JP2011515631 A JP 2011515631A JP 2011526616 A5 JP2011526616 A5 JP 2011526616A5
Authority
JP
Japan
Prior art keywords
thiazolidine
dione
methylidene
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011515631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526616A (ja
JP5261575B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/050773 external-priority patent/WO2010001169A2/en
Publication of JP2011526616A publication Critical patent/JP2011526616A/ja
Publication of JP2011526616A5 publication Critical patent/JP2011526616A5/ja
Application granted granted Critical
Publication of JP5261575B2 publication Critical patent/JP5261575B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011515631A 2008-07-02 2009-07-02 化学化合物 Expired - Fee Related JP5261575B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7763908P 2008-07-02 2008-07-02
US61/077,639 2008-07-02
US18327809P 2009-06-02 2009-06-02
US61/183,278 2009-06-02
PCT/GB2009/050773 WO2010001169A2 (en) 2008-07-02 2009-07-02 Chemical compounds 251

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013031176A Division JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Publications (3)

Publication Number Publication Date
JP2011526616A JP2011526616A (ja) 2011-10-13
JP2011526616A5 true JP2011526616A5 (US06653308-20031125-C00057.png) 2013-04-11
JP5261575B2 JP5261575B2 (ja) 2013-08-14

Family

ID=41050276

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011515631A Expired - Fee Related JP5261575B2 (ja) 2008-07-02 2009-07-02 化学化合物
JP2013031176A Ceased JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013031176A Ceased JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Country Status (27)

Country Link
US (2) US8901307B2 (US06653308-20031125-C00057.png)
EP (1) EP2310010A2 (US06653308-20031125-C00057.png)
JP (2) JP5261575B2 (US06653308-20031125-C00057.png)
KR (1) KR20110031367A (US06653308-20031125-C00057.png)
CN (2) CN103804371A (US06653308-20031125-C00057.png)
AR (1) AR072791A1 (US06653308-20031125-C00057.png)
AU (1) AU2009265362B2 (US06653308-20031125-C00057.png)
BR (1) BRPI0914599A2 (US06653308-20031125-C00057.png)
CA (1) CA2729557A1 (US06653308-20031125-C00057.png)
CL (1) CL2010001636A1 (US06653308-20031125-C00057.png)
CO (1) CO6341555A2 (US06653308-20031125-C00057.png)
CR (1) CR20110016A (US06653308-20031125-C00057.png)
DO (1) DOP2010000408A (US06653308-20031125-C00057.png)
EA (1) EA018989B1 (US06653308-20031125-C00057.png)
EC (1) ECSP10010735A (US06653308-20031125-C00057.png)
HN (1) HN2010002786A (US06653308-20031125-C00057.png)
IL (1) IL210127A0 (US06653308-20031125-C00057.png)
MX (1) MX2010014233A (US06653308-20031125-C00057.png)
MY (1) MY155961A (US06653308-20031125-C00057.png)
NI (1) NI201100007A (US06653308-20031125-C00057.png)
NZ (1) NZ590859A (US06653308-20031125-C00057.png)
PE (1) PE20120304A1 (US06653308-20031125-C00057.png)
SV (1) SV2011003786A (US06653308-20031125-C00057.png)
TW (1) TWI461423B (US06653308-20031125-C00057.png)
UY (1) UY31952A (US06653308-20031125-C00057.png)
WO (1) WO2010001169A2 (US06653308-20031125-C00057.png)
ZA (1) ZA201100844B (US06653308-20031125-C00057.png)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159449A (en) 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
TR201903488T4 (tr) 2007-06-13 2019-04-22 Incyte Holdings Corp Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT3050882T (pt) 2010-03-10 2018-04-16 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6057907B2 (ja) * 2011-10-04 2017-01-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
JP5386662B1 (ja) 2012-03-30 2014-01-15 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
TW201601769A (zh) * 2013-09-27 2016-01-16 樂敦製藥股份有限公司 皮膚外用組成物
WO2015046390A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
JPWO2015122504A1 (ja) * 2014-02-13 2017-03-30 国立大学法人 東京大学 キナーゼ阻害剤
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP5857104B2 (ja) * 2014-06-17 2016-02-10 ロート製薬株式会社 ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016100391A1 (en) 2014-12-15 2016-06-23 Prosetta Antiviral, Inc. 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds
CN105985298B (zh) * 2015-02-10 2018-02-23 湖南大学 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用
EP3265090A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating cancer associated with a ras mutation
CN106032365B (zh) * 2015-03-11 2018-03-23 湖南大学 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
CA3020161A1 (en) 2016-04-05 2017-10-12 Immune Sensor, Llc Cgas antagonist compounds
MX2018015100A (es) 2016-06-06 2019-09-04 Beyondspring Pharmaceuticals Inc Composicion y metodo para reducir la neutropenia.
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MA52219A (fr) 2018-03-30 2021-02-17 Incyte Corp Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
WO2019209083A1 (ko) * 2018-04-26 2019-10-31 재단법인 의약바이오컨버젼스연구단 mTOR 저해제로서의 신규 화합물 및 이의 용도
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
CN116354901B (zh) * 2023-04-12 2024-04-26 郑州大学 一种噻唑烷二酮类化合物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
JP3668291B2 (ja) 1995-06-16 2005-07-06 久光製薬株式会社 新規なピペリジン誘導体
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1321153A (zh) * 1999-07-01 2001-11-07 杰龙公司 端粒酶抑制剂及其使用方法
HUP0202520A3 (en) 1999-08-23 2004-11-29 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
TW593293B (en) * 1999-08-23 2004-06-21 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives
AU1595001A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153325A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
AU2004232326A1 (en) * 2003-04-18 2004-11-04 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
DE602005020611D1 (de) 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim

Similar Documents

Publication Publication Date Title
JP2011526616A5 (US06653308-20031125-C00057.png)
JP5261575B2 (ja) 化学化合物
JP2017530999A5 (US06653308-20031125-C00057.png)
JP2010513444A5 (US06653308-20031125-C00057.png)
JP2021011495A5 (US06653308-20031125-C00057.png)
JP2014511869A5 (US06653308-20031125-C00057.png)
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
JP2007523905A5 (US06653308-20031125-C00057.png)
US9580438B2 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
JP2007528887A5 (US06653308-20031125-C00057.png)
JP2007508346A5 (US06653308-20031125-C00057.png)
JP2010533158A5 (US06653308-20031125-C00057.png)
JP2018511587A5 (US06653308-20031125-C00057.png)
JP2005526814A5 (US06653308-20031125-C00057.png)
JP2005526723A5 (US06653308-20031125-C00057.png)
RU2014142598A (ru) Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
JP2007534687A5 (US06653308-20031125-C00057.png)
JP2008523006A5 (US06653308-20031125-C00057.png)
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
JP2016517878A5 (US06653308-20031125-C00057.png)
JP2012520867A5 (US06653308-20031125-C00057.png)
JP2011504497A5 (US06653308-20031125-C00057.png)
JP2007520540A5 (US06653308-20031125-C00057.png)
JP2003512353A5 (US06653308-20031125-C00057.png)
JP2007523142A5 (US06653308-20031125-C00057.png)